PCSK9 and coronary artery disorder: Studies have revealed an increased incidence of cardiovascular events and mortality in CHD patients even though diet therapy reduced total cholesterol by 13% (29), and even after the aggressive use of statins or proprotein convertase subtilisin/kexin type 9 inhibitors, which bring LDL-C down to standard, a subset of the CHD population still suffers from adverse cardiovascular events (30, 31).